103 related articles for article (PubMed ID: 11821723)
1. Restoring cellular differentiatin in posttransplant lymphoproliferative disease.
Amlot PL
Transplantation; 2002 Jan; 73(2):163-5. PubMed ID: 11821723
[No Abstract] [Full Text] [Related]
2. A histone deacetylase inhibitor, azelaic bishydroxamic acid, shows cytotoxicity on Epstein-Barr virus transformed B-cell lines: a potential therapy for posttransplant lymphoproliferative disease.
Sculley TB; Buck M; Gabrielli B; Parsons PG; Krauer KG
Transplantation; 2002 Jan; 73(2):271-9. PubMed ID: 11821743
[TBL] [Abstract][Full Text] [Related]
3. Vorinostat approved for rare lymphoma.
Thompson CA
Am J Health Syst Pharm; 2006 Nov; 63(22):2168. PubMed ID: 17090730
[No Abstract] [Full Text] [Related]
4. Post-transplant lymphoproliferative disease (PTLD): lymphokine production and PTLD.
Tosato G; Teruya-Feldstein J; Setsuda J; Pike SE; Jones KD; Jaffe ES
Springer Semin Immunopathol; 1998; 20(3-4):405-23. PubMed ID: 9870254
[No Abstract] [Full Text] [Related]
5. The novel histone deacetylase inhibitor NVP-LAQ824: an addition to the therapeutic armamentarium in leukemia?
Grant S
Leukemia; 2004 Dec; 18(12):1931-3. PubMed ID: 15496978
[No Abstract] [Full Text] [Related]
6. End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry.
Zimmermann H; Denecke T; Dreyling MH; Franzius C; Reinke P; Subklewe M; Amthauer H; Kneba M; Riess H; Trappe RU
Transplantation; 2018 May; 102(5):868-875. PubMed ID: 29189632
[TBL] [Abstract][Full Text] [Related]
7. Histone deacetylase inhibitors: development of suberoylanilide hydroxamic acid (SAHA) for the treatment of cancers.
Richon VM; Zhou X; Rifkind RA; Marks PA
Blood Cells Mol Dis; 2001; 27(1):260-4. PubMed ID: 11358386
[No Abstract] [Full Text] [Related]
8. Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials.
Zimmermann H; Babel N; Dierickx D; Morschhauser F; Mollee P; Zaucha JM; Dreyling MH; Dührsen U; Reinke P; Verhoef G; Subklewe M; Hüttmann A; Tousseyn T; Bachy E; Hauser IA; Tarella C; Van Den Neste E; Gheysens O; Anagnostopoulos I; Leblond V; Riess H; Choquet S; Trappe RU
Transplantation; 2018 Nov; 102(11):1914-1923. PubMed ID: 29757894
[TBL] [Abstract][Full Text] [Related]
9. Histone deacetylase inhibitors: Are they here to stay?
Ibrahim RB
Am J Health Syst Pharm; 2010 May; 67(10):791. PubMed ID: 20479099
[No Abstract] [Full Text] [Related]
10. The potential of histone deacetylase inhibitors for the treatment of multiple myeloma.
Prince HM; Bishton M; Harrison S
Leuk Lymphoma; 2008 Mar; 49(3):385-7. PubMed ID: 18297514
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors have antitumor activity in two NOD/SCID mouse models of B-cell precursor childhood acute lymphoblastic leukemia.
Einsiedel HG; Kawan L; Eckert C; Witt O; Fichtner I; Henze G; Seeger K
Leukemia; 2006 Aug; 20(8):1435-6. PubMed ID: 16810202
[No Abstract] [Full Text] [Related]
12. Histone deacetylase inhibitors in cancer therapy.
Fouladi M
Cancer Invest; 2006; 24(5):521-7. PubMed ID: 16939962
[No Abstract] [Full Text] [Related]
13. Posttransplant lymphoproliferative diseases: report from a single center.
Rondinara GF; Muti G; De Carlis L; De Gasperi A; Cantoni S; Slim AO; Forti D
Transplant Proc; 2001; 33(1-2):1832-3. PubMed ID: 11267532
[No Abstract] [Full Text] [Related]
14. Patterns of Epstein-Barr virus latent and replicative gene expression in Epstein-Barr virus B cell lymphoproliferative disorders after organ transplantation.
Rea D; Fourcade C; Leblond V; Rowe M; Joab I; Edelman L; Bitker MO; Gandjbakhch I; Suberbielle C; Farcet JP
Transplantation; 1994 Aug; 58(3):317-24. PubMed ID: 8053055
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of transformed cell growth and induction of cellular differentiation by pyroxamide, an inhibitor of histone deacetylase.
Butler LM; Webb Y; Agus DB; Higgins B; Tolentino TR; Kutko MC; LaQuaglia MP; Drobnjak M; Cordon-Cardo C; Scher HI; Breslow R; Richon VM; Rifkind RA; Marks PA
Clin Cancer Res; 2001 Apr; 7(4):962-70. PubMed ID: 11309347
[TBL] [Abstract][Full Text] [Related]
16. Drug insight: Histone deacetylase inhibitors--development of the new targeted anticancer agent suberoylanilide hydroxamic acid.
Kelly WK; Marks PA
Nat Clin Pract Oncol; 2005 Mar; 2(3):150-7. PubMed ID: 16264908
[TBL] [Abstract][Full Text] [Related]
17. Histone Deacetylase Inhibitors for Cutaneous T-Cell Lymphoma.
Duvic M
Dermatol Clin; 2015 Oct; 33(4):757-64. PubMed ID: 26433847
[TBL] [Abstract][Full Text] [Related]
18. CD81, a cell cycle regulator, is a novel target for histone deacetylase inhibition in glioma cells.
Gensert JM; Baranova OV; Weinstein DE; Ratan RR
Neurobiol Dis; 2007 Jun; 26(3):671-80. PubMed ID: 17481908
[TBL] [Abstract][Full Text] [Related]
19. [Basic research for renal regeneration].
Hishikawa K; Fujita T
Nihon Rinsho; 2006 Jul; 64 Suppl 5():552-8. PubMed ID: 16895225
[No Abstract] [Full Text] [Related]
20. Cell cycle arrest and lytic induction of EBV-transformed B lymphoblastoid cells by a histone deacetylase inhibitor, Trichostatin A.
Seo JS; Cho NY; Kim HR; Tsurumi T; Jang YS; Lee WK; Lee SK
Oncol Rep; 2008 Jan; 19(1):93-8. PubMed ID: 18097580
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
